Ligand-Directed Covalent Modification of Protein Kinases
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current reversible protein inhibitors face challenges such as non-selective binding due to conserved ATP-binding sites among kinases, short duration of inhibition, and toxicity issues from high plasma levels, necessitating frequent dosing and potential off-target interactions.
Innovation Solution
Designing ligands that covalently bind to lysine residues in proteins using a warhead compound with a reactive chemical moiety, allowing for prolonged inhibition by forming a covalent bond with the protein's primary amine group, thereby reducing the need for frequent dosing and minimizing toxicity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Duration of action of moving object
If reversible inhibitors are used to inhibit protein activity, then the inhibition can be controlled and reversed, but the duration of action is short and frequent dosing is required
Solution Approach 1:
The patent changes the binding mode parameter from reversible to irreversible covalent binding. The ligand is designed with a reactive warhead that forms a covalent bond with a specific amino acid residue (cysteine, lysine, or arginine) in the target protein, fundamentally altering the duration parameter from transient to permanent inhibition.
Solution Approach 2:
The ligand is designed as a composite structure combining a pharmacophore (for target recognition and binding) with a reactive warhead (for covalent modification). This composite design enables both selective target engagement and irreversible inhibition, resolving the contradiction between controllability and duration.
2Reliability
If high plasma concentrations are used to maintain therapeutic activity, then efficacy is improved, but toxicity and off-target interactions increase
Solution Approach 1:
The patent extracts the reversible binding requirement by implementing irreversible covalent binding. The warhead forms a permanent covalent bond with the target protein, eliminating the need for sustained plasma concentrations and thereby removing the source of concentration-dependent toxicity.
Solution Approach 2:
The patent changes the pharmacokinetic parameter from requiring sustained plasma concentration to requiring brief exposure. The irreversible binding mechanism allows the drug to be administered at lower concentrations for shorter durations, fundamentally altering the concentration-time profile and reducing toxic exposure.
3Adaptability or versatility
If reversible inhibitors bind to conserved ATP-binding sites, then broad kinase inhibition is achieved, but selectivity among specific kinases is lost
Solution Approach 1:
The patent applies local quality by directing the reactive warhead to modify a specific amino acid residue (cysteine, lysine, or arginine) within or near the ATP-binding site. This localized covalent modification provides selectivity based on the presence and accessibility of the target residue, while the pharmacophore maintains broad kinase recognition.
Solution Approach 2:
The patent introduces the reactive warhead as an intermediary that mediates between the pharmacophore (which provides broad kinase recognition) and the target protein (which provides selectivity through specific residue modification). The warhead acts as the selective element that distinguishes between different kinases based on residue accessibility and chemistry.
4Reliability
If highly reactive reagents are used for lysine modification, then covalent binding is achieved, but non-specific off-target reactions occur
Solution Approach 1:
The patent applies local quality by designing the warhead to react with specific amino acid residues (cysteine, lysine, or arginine) based on their local chemical environment within the target protein's binding site. The selective reactivity is determined by the local structure, accessibility, and chemical properties of the target residue, not by bulk reactivity.
Solution Approach 2:
The patent introduces the warhead as a selective intermediary that mediates covalent binding with specific amino acid residues. The warhead's reactivity is tuned to recognize and react with particular residues (cysteine, lysine, or arginine) based on their chemical properties and local environment, acting as a selective gatekeeper that prevents non-specific reactions while enabling target covalent modification.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enables prolonged suppression of target proteins with reduced toxicity and off-target interactions, maintaining therapeutic activity with lower plasma concentrations, and overcoming drug resistance by ensuring irreversible inhibition.
Implementation Method 1
Designing ligands that covalently bind to lysine residues in proteins using a warhead compound with a reactive chemical moiety, allowing for prolonged inhibition by forming a covalent bond with the protein's primary amine group
Data Source
AI summary
The present invention relates to enzyme inhibitors. More specifically, the present invention relates to ligand-directed covalent modification of proteins; method of designing same; pharmaceutical formulation of same; and method of use.